Ingersoll Rand Inc. IR
Composite 41/100; the shares have moved about 36% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 21/100 — a strong mark against it.
Balance-sheet strength ranks 60/100 — a slight point in its favour. Valuation ranks 58/100 — a slight point in its favour.
Growth ranks 21/100 — a strong mark against it. Quality ranks 28/100 — a moderate mark against it. Income ranks 34/100 — a moderate mark against it.
What the company does Ingersoll Rand Inc. (IR) designs and manufactures mission-critical air, fluid, clean energy, and medical technologies, including compression systems, pumps, and precision dosing equipment under brands like Ingersoll Rand and Gardner Denver.
Key financials IR’s profitability metrics show mixed quality: ROE 9.5%, ROA 5.1%, and ROCE 9.4%, with gross margins at 42.8% but net margins at 12.1%. Revenue grew 5.8% while EPS declined -30.2%, reflecting margin pressure. Debt/equity stands at 0.48 and interest coverage at 5.70x.
Stock health Momentum is weak: 12-month return is 0.66%, trailing 6 months -18.32%, and RSI(14) at 38.80 signals oversold conditions. The stock is -21.37% below its 52-week high, with a beta of 1.16 indicating above-market volatility.
Price vs fair value The stock trades at a discount of 21.30% versus the analyst mean target of 96.25. - Forward P/E of 24.39 is below the trailing P/E of 34.97, suggesting a valuation gap. - Nordson’s earnings outlook may signal sector caution (Zacks, 2026-08-17). - Sidera’s Valuation percentile of 38.0/100 aligns with a fairly valued stance.
Looking forward Forward PEG of 0.56 indicates potential value relative to growth, but weak momentum (40.9) and income (34.0) scores temper optimism. Focus on margin recovery and execution in Precision & Science Technologies to support the valuation case.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.